Navigation Links
Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
Date:7/3/2008

IRVINE, Calif., July 3 /PRNewswire/ -- Antigen Discovery Inc. ("ADI", formerly ImmPORT Therapeutics Inc.), a leader in high throughput antigen/biomarker discovery using advanced genomics and proteomics tools, announced today that the Company was awarded a Phase II SBIR from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Center for Research Resources (NCRR). The $3 million grant will fund efforts to further develop ADI's protein microarray based serodiagnostic platform for applications in biodefense and emerging infectious diseases. ADI will collaborate with investigators at the Proteomics Core facility of the Pacific Southwest Regional Center of Excellence (PSW RCE), located at the University of California, Irvine.

"The major bottleneck that limits the translation of readily available genomic information into the development of next generation diagnostics, vaccines and therapeutics, is the continued lack of effective antigen and biomarker discovery tools," said Dr. Xiaowu Liang, CEO of ADI. "We are grateful that the SBIR program continues to fund ADI and our UCI collaborators in the further development of this exciting new technology platform that truly revolutionizes the screening and detection of disease markers."

"The focus of this grant is to commercialize some of the broad applications of the platform technology that were developed during previous funding phases. The establishment of a Good Manufactuing Practices (GMP) facility, and a Clinical Research Lab will enable us to offer diagnostic products and services to physicians, point of care facilities, developers of novel vaccines, and pharmaceutical researchers," added Dr. Huw Davies, the Principal Investigator on the SBIR grant. "By using our novel protein array systems and statistical algorithms, we can rapidly discover antigen sets that will provide serological tests that discriminate between different infections, or even between different stages of t
'/>"/>

SOURCE Antigen Discovery Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
2. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
5. Discovery by UC Riverside physicists could enable development of faster computers
6. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
7. Oncomine(TM) Again Key to Prostate Cancer Discovery
8. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
9. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
10. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
11. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... ... 01, 2015 , ... A newly launched business plan contest will ask startup ... innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see ... a period of expert mentorship from a senior industry figure drawn from the Pistoia ...
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
(Date:7/1/2015)... July 1, 2015  UCB, a multinational biopharmaceutical ... global leader in designing, transforming, and running intelligent ... in recognition of their close collaboration in driving ... global business services (GBS) finance organization. ... clients that work together effectively to embrace the ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... (NASDAQ: AMGN ) today announced the submission of ... and Drug Administration (FDA) to expand the indication for XGEVA® ... the risk of developing bone metastases. If approved, XGEVA would ... spread of cancer to the bone. The ...
... June 27, 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ... arising out of a blog post on Friday, June ... the Company,s common stock fell more than 20% and ... (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) The author of the blog ...
... Md., June 27, 2011 PharmAthene, Inc. (NYSE Amex: ... achieved an important technical milestone in its recombinant protective ... initial technology transfer of its manufacturing process for the ... the 100 liter scale to a US-based manufacturing facility ...
Cached Biology Technology:Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 2Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 3Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 4Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 5Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 6Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 7Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 8Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 9Generex Provides Clarification of Facts 2Generex Provides Clarification of Facts 3Generex Provides Clarification of Facts 4Generex Provides Clarification of Facts 5PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 2PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 3
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... 20 August 2010 - Pharma-Nutrition, the new international ... of scientific, technical and medical information products and ... and practical applications of medical nutrition in patient ... is set to take place next 18-20 April ...
... CHAPEL HILL Researchers at the University of North Carolina ... architecture controlling the growth of the collateral circulation the ... in the event of a heart attack or stroke. ... what are called collaterogenic therapies drugs or procedures that ...
... Four" Sherlock Holmes tells Watson he has written a monograph ... plates illustrating the difference in the ash." He finds the ... smoke during the commission of a crime. But Sherlock ... a patch on geologists and the "redox proxies" from which ...
Cached Biology News:Genetics underlie formation of body's back-up bypass vessels 2Geologists revisit the Great Oxygenation Event 2Geologists revisit the Great Oxygenation Event 3Geologists revisit the Great Oxygenation Event 4Geologists revisit the Great Oxygenation Event 5Geologists revisit the Great Oxygenation Event 6
Bovine Serum...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Quartz-Halogen, 100 W, High Intensity...
Biology Products: